A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy

Clinical Breast Cancer

Volumn 2, Issue 4, 2002, Pages 282-286

  Gradishar, William J ^a   Hellmund, Richard ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Adjuvant duration; Reinitiation; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT;

EID: 0036187733     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.n.003     Document Type: Review

References (18)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women
3. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
4. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
5. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
6. Dormancy of mammary carcinoma after mastectomy
7. Contralateral breast carcinoma: An assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up
8. Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial
9. Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)
10. Delayed adjuvant tamoxifen in postmenopausal women with axillary node-negative breast cancer: Mortality over 10 years
11. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
12. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer
13. Tamoxifen-the treatment of choice. Why look for alternatives?
14. Five years of tamoxifen-or more?
15. Prolonged follow-up of the Swedish Randomized Trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer and relationships to hormone receptor and ERBB2 levels
16. Tamoxifen in the treatment of breast cancer
17. Tamoxifen therapy for breast cancer and endometrial cancer risk
18. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer